[go: up one dir, main page]

WO2007017652A3 - Utilisation therapeutique - Google Patents

Utilisation therapeutique Download PDF

Info

Publication number
WO2007017652A3
WO2007017652A3 PCT/GB2006/002930 GB2006002930W WO2007017652A3 WO 2007017652 A3 WO2007017652 A3 WO 2007017652A3 GB 2006002930 W GB2006002930 W GB 2006002930W WO 2007017652 A3 WO2007017652 A3 WO 2007017652A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
arylakylamines
pyridineethanamine
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/002930
Other languages
English (en)
Other versions
WO2007017652A2 (fr
Inventor
Reginald Bowie Ewesuedo
Gerardus Johannes Cl Kolvenbag
Dennis Joseph Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2007017652A2 publication Critical patent/WO2007017652A2/fr
Publication of WO2007017652A3 publication Critical patent/WO2007017652A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'arylalkyl-amines et d'arylalkyl-amides, en particulier, (S)-a-phenyl-2-pyridineethanamine, ou des sels de ceux-ci pharmaceutiquement acceptables pour traiter le cancer chez un animal à sang chaud, tel que l'homme. D'autres aspects de l'invention concernent une méthode permettant de traiter le cancer, et l'utilisation d'arylalkyl-amines et d'arylalkyl-amides, en particulier, (S)-a-phenyl-2-pyridineethanamine, ou des sels de ceux-ci pharmaceutiquement acceptables pour produire un médicament utilisé dans ladite méthode de traitement du cancer.
PCT/GB2006/002930 2005-08-10 2006-08-08 Utilisation therapeutique Ceased WO2007017652A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70691605P 2005-08-10 2005-08-10
US60/706,916 2005-08-10

Publications (2)

Publication Number Publication Date
WO2007017652A2 WO2007017652A2 (fr) 2007-02-15
WO2007017652A3 true WO2007017652A3 (fr) 2007-05-31

Family

ID=37727678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002930 Ceased WO2007017652A2 (fr) 2005-08-10 2006-08-08 Utilisation therapeutique

Country Status (1)

Country Link
WO (1) WO2007017652A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208438A4 (fr) * 2020-08-28 2025-01-22 The Regents of the University of California Compositions et méthodes de traitement d'états pathologiques liés aux amyloïdes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011995A1 (fr) * 1988-08-12 1991-08-22 Fisons Corporation Arylalkyl-amines et -amides possedant des proprietes anticonvulsives et neuroprotectrices
WO1993020052A1 (fr) * 1992-04-03 1993-10-14 Fisons Corporation 1-phenyl-2-(2-pyridinyl)ethylamine enantiomere pour le traitement de maladies de degenerescence du systeme nerveux
WO2000024395A1 (fr) * 1998-10-28 2000-05-04 Hrissanthi Ikonomidou Nouvelle utilisation d'antagonistes du glutamate pour le traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011995A1 (fr) * 1988-08-12 1991-08-22 Fisons Corporation Arylalkyl-amines et -amides possedant des proprietes anticonvulsives et neuroprotectrices
WO1993020052A1 (fr) * 1992-04-03 1993-10-14 Fisons Corporation 1-phenyl-2-(2-pyridinyl)ethylamine enantiomere pour le traitement de maladies de degenerescence du systeme nerveux
WO2000024395A1 (fr) * 1998-10-28 2000-05-04 Hrissanthi Ikonomidou Nouvelle utilisation d'antagonistes du glutamate pour le traitement du cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREENE J G ET AL: "ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology.", EXPERIMENTAL NEUROLOGY JAN 1996, vol. 137, no. 1, January 1996 (1996-01-01), pages 66 - 72, XP002421391, ISSN: 0014-4886 *
HARTWELL, JONATHAN L. ET AL: "Chemical treatment of tumors. XI. Some .alpha.,.beta.- diphenylethylamines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 67, 1606-8 CODEN: JACSAT; ISSN: 0002-7863, 1945, XP002421390 *
LEITER J ET AL: "Negative results with diphenylethylamines in producing damage in sarcoma 37.", CANCER RESEARCH 1955, vol. Suppl. 2, 1955, pages 109 - 123, XP002421389, ISSN: 0008-5472 *
OWARI S: "Effect of alpha,beta-diphenylethylamines upon Yoshida sarcoma.", PHARMACEUTICAL BULLETIN JUN 1953, vol. 1, no. 2, June 1953 (1953-06-01), pages 174 - 176, XP009079500 *

Also Published As

Publication number Publication date
WO2007017652A2 (fr) 2007-02-15

Similar Documents

Publication Publication Date Title
WO2007087395A3 (fr) INHIBITEURS DE mTOR INSATURES
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2008075068A3 (fr) Nouveaux composés
WO2009050506A3 (fr) Combinaison 059
WO2007061737A3 (fr) INHIBITEURS mTOR BICYCLIQUES CONDENSES
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2008127594A3 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
WO2004071382A3 (fr) Heterocycles substitues
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
TNSN07294A1 (en) Treatment of metastasized tumors
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
WO2007107748A3 (fr) Inhibition de la croissance tumorale
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
WO2010025135A3 (fr) Dérivés de triméprazine et d’éthopropazine pour favoriser la croissance osseuse
WO2006102375A3 (fr) Methodes pour eviter un oedeme dans le traitement ou la prevention de maladies sensibles a ppar$g(g), telles que le cancer
WO2010107791A3 (fr) Composés de pyrazinoisoquinoline
WO2008109521A3 (fr) Procédé de traitement utilisant de l'atranorine
PL1979053T3 (pl) Produkt do leczenia skóry i błon śluzowych oraz odnośny sposób wytwarzania
MY140538A (en) Substituted n-acyl-2-aminothiazoles
WO2008057313A3 (fr) Procédés d'utilisation de e2f2 pour le traitement de l'hypertension
WO2007146375A3 (fr) Composés de pyrimido-dione-quinoléine hautement solubles et procédés de traitement du cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765232

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765232

Country of ref document: EP

Kind code of ref document: A2